Introduction {#sec1_1}
============

Acute kidney injury (AKI) is a common condition and is associated with an increased risk of in-hospital mortality and heightened resource consumption, including prolonged hospitalization and greater healthcare expenditures \[[@B1], [@B2]\]. Although reactive oxygen species (ROS) have been incriminated in the pathogenesis and evolution of AKI \[[@B3], [@B4], [@B5], [@B6], [@B7], [@B8], [@B9]\], there is significant unexplained variability in the prediction of adverse kidney-related outcomes \[[@B10], [@B11]\].

In recent years, several genetic polymorphisms have been explored as potential determinants of disease severity and adverse outcomes in patients with AKI \[[@B12], [@B13], [@B14], [@B15], [@B16], [@B17], [@B18]\]. An important source of ROS in AKI is NADPH oxidase (NOX), an enzyme complex that primarily produces superoxide \[[@B19]\]. This enzyme has multiple components, including 2 transmembrane subunits (gp91^phox^ and p22^phox^), 3 cytosolic subunits (p40^phox^, p47^phox^, and p67^phox^), and a GTP-binding protein (p21).

The p22^phox^ subunit is the final transporter in the chain transferring electrons from NADPH to molecular oxygen, and is encoded by the α subunit of the cytochrome b~245~*(CYBA)* gene, which is located on chromosome 16q24. Several polymorphisms in the *CYBA* gene have been described, some of which have been associated with increased \[[@B20]\] or decreased NOX activity \[[@B21]\], as well as reduced ROS generation \[[@B22], [@B23]\]. Genetic variation in the expression of this key enzyme might account for the interindividual variability observed in the manifestation of AKI. The aim of the present study was to examine whether 5 key polymorphisms in the *CYBA* gene locus and corresponding haplotypes are associated with disease severity and adverse outcome in hospitalized AKI patients.

Patients and Methods {#sec1_2}
====================

Study Design and Participants {#sec2_1}
-----------------------------

This was a prospective cohort study of hospitalized AKI patients, which was conducted at two tertiary care hospitals (Boston, Mass., USA). All consecutive hospitalized adults with AKI, in whom nephrology consultation was requested, were eligible for enrollment. AKI was defined according to the criteria by Hou et al. \[[@B24]\], i.e. a rise in serum creatinine by 0.5, 1.0, or 1.5 mg/dl from a baseline level ≤1.9, 2.0--4.9, or ≥5.0 mg/dl, respectively. This definition was adopted prior to the development of the more recent AKI network consensus definition \[[@B25]\]. However, we used this classification to categorize AKI stages.

Exclusion criteria were age \<18 years, pregnancy, long-term dialysis, organ transplantation within the prior year, and presence of acute obstructive uropathy. Institutional review board approval was granted, and written informed consent was obtained from all participants or next of kin.

Data Collection {#sec2_2}
---------------

Hospital records were reviewed prospectively to retrieve information on baseline demographic characteristics, coexisting conditions, and kidney-related variables, including serial serum creatinine values and 24-hour urine output at enrollment. Sepsis was ascertained using the systemic inflammatory response syndrome criteria \[[@B26]\], and two severity-of-illness scores were calculated, the APACHE II (Acute Physiology and Chronic Health Evaluation) score \[[@B27]\] and the MOF (Multiple Organ Failure) score \[[@B28]\]. Preexisting chronic kidney disease was defined on the basis of a baseline estimated glomerular filtration rate \<60 ml/min/1.73 m^2^, which was calculated using the MDRD (Modification of Diet in Renal Disease) equation \[[@B29]\].

Blood and Urine Sampling {#sec2_3}
------------------------

At enrollment, EDTA-anticoagulated whole blood and urine were collected. Plasma was separated, and the remaining blood was aliquoted for subsequent DNA extraction. Either freshly voided urine or urine from the access port of a Foley catheter was obtained, kept on ice and processed within 30 min after collection. Samples were centrifuged for 10 min at 3,000 rpm, treated with a protease inhibitor cocktail (Complete Mini; Roche Diagnostics, Mannheim, Germany) and then aliquoted. All samples were stored at −80°C.

Selection Criteria and TaqMan Genotyping Analyses {#sec2_4}
-------------------------------------------------

To obtain a comprehensive representation of the genetic variability in the *CYBA* gene locus (reference sequence GeneBank accession No. NM 000101.2), we selected the genetic variants according to several criteria, including published reports on investigated clinical and functional associations; variants with at least 10% minor allele frequency, and variants preferentially located in the promoter, coding, non-coding, and untranslated regions (UTR). Through this careful selection process, we identified the following 5 polymorphisms of interest in the C*YBA* gene locus: promoter −1442 (G→A, reference single nucleotide polymorphism, refSNP, rs8854), intron 1 +383 (G→A, refSNP rs3794624), exon 4 +242 (C→T, refSNP rs4673), and 3′-UTR +8897 (A→T, refSNP rs4782390), and +640 (A→G, refSNP rs1049255).

Genomic DNA was prepared from whole blood leukocytes using the QiAmp DNA blood kit (Qiagen, Valencia, Calif., USA). DNA samples were then genotyped by combining the TaqMan universal PCR master mix with the TaqMan SNP genotyping assay into a 384-well plate using the Applied Biosystems 7900HT fast real-time PCR system (Applied Biosystems, Foster City, Calif., USA) according to a standardized protocol. Resulting sequences were analyzed by the SNP software (SDS version 2.2), which uses an advanced multi-component algorithm to calculate distinct allele/marker signal contributions from fluorescence measurements for each sample well during the assay plate read with the SNP auto-caller. The SNP auto-caller automatically determines sample genotypes and generates a cluster plot to better visualize data across samples. Pairwise patterns of linkage disequilibrium (LD) across the *CYBA* gene locus were visualized by Haploview ([www.broadinstitute.org](http://www.broadinstitute.org)), plotting LD as the D′ parameter (scaled from 0 to 100), and excluding the polymorphism(s) that did not meet the Hardy-Weinberg equilibrium. Haplotypes were imputed from the *CYBA* polymorphism diploid genotypes using PLINK ([http://pngu.mgh.harvard.edu/∼purcell/plink/](http://pngu.mgh.harvard.edu/~purcell/plink/)). The most frequent haplotype across the 4 polymorphisms in Hardy-Weinberg equilibrium (rs4782390, rs4673, rs3794624, and rs8854) was A-A-G-G, and was expressed as the number of chromosomal copies of the haplotype (0, 1, and 2) for each patient.

Measurement of Markers of Oxidative Stress {#sec2_5}
------------------------------------------

To evaluate whether the *CYBA* gene polymorphisms were associated with markers of oxidative stress, we measured plasma nitrotyrosine (a byproduct of superoxide and nitric oxide generation) and urinary 15-F~2t~-isoprostane (a marker of lipid peroxidation). All measurements were performed in duplicate. In brief, plasma nitrotyrosine was measured by sandwich ELISA (OxisResearch, Foster City, Calif., USA; results are reported in n*M*). Urinary 15-F~2t~-isoprostane was measured by competitive ELISA (Northwest Life Science Specialties, LLC, Vancouver, Wash., USA). The results were normalized to urinary creatinine (expressed as ng/mg of creatinine).

Outcome Measures {#sec2_6}
----------------

Our primary outcome of interest was the composite of dialysis requirement or in-hospital death. Our secondary outcome was the composite of dialysis requirement, assisted mechanical ventilation, or in-hospital death.

Statistical Analyses {#sec2_7}
--------------------

The genotype frequencies were tested for Hardy-Weinberg equilibrium using a standard χ^2^ test for any deviation in the observed frequencies. Comparisons between genotype groups were made by the Kruskal-Wallis test and the two-tailed Mann-Whitney test for continuous variables, and the χ^2^ or Fisher exact test for categorical variables. Results are expressed as means (SD), medians, or percentages.

Using dominant genetic models (i.e., one or two copies of the minor allele), multivariable logistic regression analyses were performed to examine the association of each *CYBA* gene polymorphism with the aforementioned primary and secondary endpoints. All models were adjusted for sex, race, and age (model 1), or sex, race, and the APACHE II score (model 2). Sepsis was added as a covariate in sensitivity analyses. The results of the logistic regression analyses are displayed as odds ratio (OR) with 95% confidence interval (CI). Using a stepwise forward and backward selection process, logistic regression analyses were also performed to identify potential haplotypes that are associated with the outcomes of interest. Only *CYBA* gene polymorphisms that were associated with the primary composite outcome on univariate analyses, using a value of p \< 0.1, were selected for the haplotype analyses.

All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, N.C., USA). Differences were considered statistically significant at p \< 0.05.

Results {#sec1_3}
=======

Characteristics of the AKI Cohort Stratified by CYBA Gene Polymorphisms {#sec2_8}
-----------------------------------------------------------------------

Between November 2003 and February 2010, a total of 264 participants were enrolled in the study, of which 2 were excluded due to study ineligibility and lack of genomic DNA sampling. The present analysis includes 262 participants who underwent genotyping analyses. At enrollment, mean age was 66 years, 53% were men, and 91% were of white ethnicity. Mean APACHE II score was 20, and 73% were in the intensive care unit. The majority of the subjects had severe AKI, as defined by the AKI network criteria, with 136 (52%) fulfilling stage-3 AKI. In-hospital mortality was 22%, 24% required mechanical ventilation, 39% required dialysis, and 47% experienced the composite outcome of dialysis requirement or in-hospital death.

Genotyping was successfully performed on 256--262 subjects. As shown in table [1](#T1){ref-type="table"}, only 1 of the 5 *CYBA* gene polymorphisms (rs8854) had a minor allele frequency \<10%. Tests for Hardy-Weinberg equilibrium revealed no deviation from expected frequencies with the exception of the *CYBA* rs1049255 polymorphism.

The characteristics of the AKI cohort stratified by the 5 *CYBA* gene polymorphisms are shown in table [2](#T2){ref-type="table"}. In brief, overall patient demographics, co-morbidities and disease severity measures did not significantly differ across genotypes, with a few notable exceptions. The *CYBA* rs8854 minor A-allele (GA/AA genotype) group had a lower prevalence of sepsis (p = 0.03) and shock (p = 0.02) compared with the GG genotype group; the *CYBA* rs4782390 minor T-allele (AT/TT genotype) group had a higher prevalence of shock (p = 0.04) compared with the AA genotype group, and the *CYBA* rs1049255 minor G-allele (AG/GG genotype) group had a higher APACHE II score (p = 0.01) compared with the AA genotype group. A genotype-phenotype association was not demonstrable between individual *CYBA* gene polymorphisms and 2 markers of oxidative stress, plasma nitrotyrosine and urinary 15-F~2t~-isoprostane levels (table [2](#T2){ref-type="table"}).

CYBA Gene Polymorphisms and Adverse Outcomes {#sec2_9}
--------------------------------------------

Compared with the GG genotype group, the *CYBA* rs8854 A-allele group experienced less dialysis requirement or in-hospital death (50 vs. 29%; p = 0.02). Figure [1](#F1){ref-type="fig"} displays the outcome of dialysis requirement or in-hospital death stratified by *CYBA* rs8854 genotypes and APACHE II score tertiles. The outcome of dialysis requirement or in-hospital death was overall less frequent among A-allele carriers within each APACHE II score tertile but within the highest APACHE II score tertile, the composite outcome was significantly lower in the *CYBA* rs8854 A-allele compared with the GG genotype group (40 vs. 80%; p = 0.006).

As shown in table [3](#T3){ref-type="table"}, the *CYBA* rs8854 A-allele group had an unadjusted OR of 0.40 (95% CI 0.19--0.88) for the outcome of dialysis requirement or in-hospital death compared with the GG genotype group. This association persisted after adjustment for sex, race, and age (OR 0.39; 95% CI 0.18--0.85), as well as sex, race, and APACHE II score (OR 0.41; 95% CI 0.18--0.96). A similar association was observed after adjustment for sex, race, APACHE II score, and sepsis (data not shown). The *CYBA* rs8854 A-allele group was also associated with the secondary outcome of dialysis requirement, assisted mechanical ventilation, or in-hospital death after adjustment for sex, race, and age (OR 0.42; 95% CI 0.20--0.89), as well as sex, race and APACHE II score (OR 0.43; 95% CI 0.18--0.99).

By contrast, the *CYBA* rs4673 T-allele and rs1049255 G-allele group had an unadjusted OR of 1.69 (95% CI 1.03--2.79) and 1.66 (95% CI 1.01--2.73) for the outcome of dialysis requirement or in-hospital death compared with the CC genotype and AA genotype group, respectively (table [3](#T3){ref-type="table"}). These associations were attenuated after adjustment for sex, race, and age, but became non-significant once adjusted for the APACHE II score. There was not any association between the *CYBA* rs3794624 or rs4782390 polymorphism and the primary and secondary composite outcomes (table [3](#T3){ref-type="table"}).

CYBA Haplotypes and Adverse Outcomes {#sec2_10}
------------------------------------

We next generated a Haploview plot on 4 *CYBA* gene polymorphisms after exclusion of rs1049255, which did not fulfill Hardy-Weinberg equilibrium. Figure [2](#F2){ref-type="fig"} displays the LD plot at the *CYBA* gene locus with representation of the 4 variants analyzed in our study cohort. The LD plot revealed substantial correlation (as defined by the D′ parameter) across the ∼8-kbp human *CYBA* locus, with the rs8854 and rs4673 polymorphisms displaying the highest correlation, as evidenced by a D′ parameter of 85 (on a scale of 0--100).

Finally, we conducted haplotype analyses after excluding the polymorphism that did not fulfill the Hardy-Weinberg equilibrium (rs1049255). The most frequent haplotype was A-A-G-G estimated on 186 chromosomes with a frequency of 56.5%. As shown in table [3](#T3){ref-type="table"}, the presence of one copy of this common haplotype was associated with an OR of 1.81 (95% CI 1.07--3.08) for the outcome of dialysis requirement or in-hospital death, which persisted after adjustment for sex, race, and age (OR 1.76; 95% CI 1.03--3.01), but was attenuated after adjustment for sex, race, and APACHE II score (OR 1.80; 95% CI 0.99--3.29). The haplotype A-A-G-G association was directionally consistent with that observed for the *CYBA* rs4673 polymorphism. Of note, however, there was no association with the presence of two copies of the *CYBA* A-A-G-G haplotype.

Discussion {#sec1_4}
==========

In the present study, we examined the relationship of 5 polymorphisms in the *CYBA* gene locus located in the promoter (rs8854), intron-1 (rs3794624), exon-4 (rs4673), and 3′-UTR (rs4782390 and rs1049255) regions, with adverse clinical outcomes in a large cohort of hospitalized patients with AKI. The observed and expected genotype frequencies were not significantly different, with the exception of *CYBA* rs1049255, which did not fulfill Hardy-Weinberg equilibrium. Although the overall population was 91% white, there were no race, sex, or age differences within genotype groups with the exception of *CYBA* rs4782390 and rs1049255, which displayed race differences in allele frequencies. There was no demonstrable genotype-phenotype association between the 5 *CYBA* gene polymorphisms and the two selected markers of oxidative stress, plasma nitrotyrosine and urinary 15-F~2t~-isoprostane levels. The *CYBA* rs8854 A-allele group experienced a lower requirement for the *primary* composite outcome of dialysis requirement or in-hospital death even among patients with the highest APACHE II score. After adjustment for sex, race, and APACHE II score, the *CYBA* rs8854 A-allele group also experienced lower odds for this adverse outcome as well as for the *secondary* composite of dialysis requirement, assisted mechanical ventilation or in-hospital death. By contrast, the *CYBA* rs4673 T-allele and rs1049255 G-allele groups had higher unadjusted odds for dialysis requirement or in-hospital death, which became non-significant once adjusted for the APACHE II score. We found no association between the *CYBA* rs3794624 or rs4782390 polymorphisms and the two outcomes of interest. Finally, we identified a common haplotype (generated from the *CYBA* rs4782390, rs4673, rs3794624, and rs8854 polymorphisms) whereby the presence of a single copy, not 2 copies, was associated with higher odds for the primary outcome.

NADPH oxidase is a key enzyme that catalyzes the production of superoxide, mediating the downstream generation and injurious effects of ROS. This enzyme is highly expressed in neutrophils and endothelial cells \[[@B30]\] and possesses several subunits, including the p22^phox^ subunit, which serves as the final transporter transferring an electron from NADPH to molecular oxygen. This key electron transfer protein is encoded by the *CYBA* gene. Given its importance in mediating oxidative stress-mediated cellular injury in response to ischemic and toxic kidney injury, one might anticipate that polymorphisms disrupting the function or expression of the NOX p22^phox^ subunit would alter oxidative stress--mediated cellular responses in AKI. Several polymorphisms have been described in the *CYBA* gene that are variably linked to measures of oxidative stress, including the *CYBA* rs1049255 (3′-UTR) polymorphism, which has been associated with lower mRNA and protein expression and reduced NOX activity \[[@B22], [@B23], [@B31], [@B32]\], the *CYBA* rs4673 (Tyr^72^His, exon 4) polymorphism (associated with reduced NOX activity \[[@B21]\]); the *CYBA* rs9932581 (not studied here) polymorphism (linked to higher promoter activity \[[@B32]\] and increased NOX activity \[[@B20]\]), and the *CYBA* rs8854 (upstream, promoter) polymorphism (not linked to a change in NOX activity \[[@B33]\]). In recent years, the relationship between genetic variability in the *CYBA* gene and disease has become a topic of interest. Indeed, genetic studies of cardiovascular disease examining the influence of these polymorphisms have yielded conflicting results. Specifically, the *CYBA* rs1049255 (3′-UTR) polymorphism was linked to increased disease susceptibility; the *CYBA* rs4673 (Tyr^72^His) and rs9932581 polymorphisms to decreased disease susceptibility \[[@B34], [@B35]\], and the rs4673 polymorphism to disease progression \[[@B36]\]. Genetic studies of kidney disease have shown a protective effect of the *CYBA* rs4673 polymorphism against the development of chronic kidney failure \[[@B37]\], and in a previously reported subgroup of the present study cohort, we found the rs4673 polymorphism to be associated with higher odds for dialysis requirement or in-hospital death \[[@B13]\]. In the present study, the effect estimate of this polymorphism was in the same direction but was attenuated in the adjusted analyses.

In the present study, the potential mechanisms underlying the harmful association of the common *CYBA* A-A-G-G haplotype with the composite of dialysis requirement or in-hospital death are unknown. We propose that the worse outcomes observed amongst carriers of this haplotype might in part be due to the increased generation of ROS by NOX residing in neutrophils and endothelial cells, resulting in more extensive organ injury. However, this hypothesis requires further study.

To our knowledge, this is the first comprehensive study testing the comprehensive hypothesis of whether 5 representative polymorphisms spanning the entire *CYBA* gene locus associate with clinical outcomes in patients with AKI. The heterogeneity of our cohort was offset by the selective inclusion of subjects with more advanced AKI requiring formal nephrology consultation. Although sizeable, our cohort was relatively small for genetic epidemiological studies, but 91% of the study cohort were white, reducing the potential impact of race and ethnicity on genotype prevalence. Although we found some ethnic differences in allele frequencies among the *CYBA* rs4782390 and rs1049255 genotypes, when the analyses were adjusted for race/ethnicity, the point estimates were not significantly altered. The use of the APACHE II score as a covariate to reflect the severity of illness strengthens the plausibility of our results. Finally, our composite endpoints were chosen to account for survival bias when dialysis requirement and assisted mechanical ventilation are being assessed as outcome measures.

The present study suffers from several limitations. First, the *CYBA* rs1049255 polymorphism did not fulfill the Hardy-Weinberg equilibrium. A similar deviation has previously been noted for the *CYBA* rs8854 polymorphism \[[@B33]\], and might in part be due to our relatively modest sample size or natural selection. A likely explanation of Hardy-Weinberg equilibrium deviation is combining two biogeographic ancestries in the Hardy-Weinberg equilibrium analysis. Second, the lack of demonstrable *CYBA* genotype-phenotype associations in terms of oxidative stress markers compromises the credibility of the observed association between the various polymorphic alleles and the two composite outcomes. Third, we had no access to a replication cohort to validate our findings. Finally, although there is the possibility that the observed associations of individual *CYBA* gene polymorphisms with outcomes might be the result of LD with other neighboring genetic variants within the locus, our haplotype analysis generated on the 4 *CYBA* gene polymorphisms provides a potential biological rationale for our results.

In conclusion, the present study helps to unravel the complex nature of how genetic variants in the *CYBA* gene locus might influence NOX activity and ROS generation, and supports the hypothesis that polymorphisms in the *CYBA* gene locus may improve the prediction of adverse outcomes in hospitalized AKI patients. Larger validation cohort studies are needed to replicate these findings.
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###### 

Observed and expected distribution of *CYBA* gene polymorphisms in the AKI cohort

  Locus    RefSNP dbSNP No.   SNP         Domain               Samples successfully genotyped, n   Variant allele (frequency)   Hardy-Weinberg equilibrium   
  -------- ------------------ ----------- -------------------- ----------------------------------- ---------------------------- ---------------------------- ----------
  *CYBA*   rs8854             −1442 G→A   promoter             262                                 A (7%)                       2.22                         0.14
  *CYBA*   rs3794624          383 G→A     intron 1             257                                 A (33%)                      0.19                         0.66
  *CYBA*   rs4673             242 C→T     exon4 (Tyr^72^His)   262                                 T (38%)                      1.71                         0.19
  *CYBA*   rs4782390          8897 A→T    3\'-UTR              260                                 T (32%)                      0.27                         0.60
  *CYBA*   rs1049255          640 A→G     3\'-UTR              256                                 G (36%)                      1.09                         \<0.0001

###### 

Enrollment characteristics of the AKI cohort according to the 5 *CYBA* gene polymorphisms

  Characteristic                         rs8854 genotypt   P value          rs3794624 genotypes   P value          rs4673 genotypes   P value   rs4782390 genotypes   P value          rsl049255 genotypes   P value                                                                     
  -------------------------------------- ----------------- ---------------- --------------------- ---------------- ------------------ --------- --------------------- ---------------- --------------------- ---------------- ---------------- ------- ---------------- ---------------- -------
  *Age, years*                           66 (15)           66 (18)          0.81                  67 (15)          65 (16)            0.38      65 (16)               67 (15)          0.32                  66 (15)          65 (16)          0.61    65 (15)          67 (16)          0.53
  *Males, %*                             52                60               0.35                  52               54                 0.72      50                    55               0.40                  55               50               0.36    54               52               0.80
  *Race, %*                                                                 0.83                                                      0.49                                             0.11                                                    0.003                                     0.006
  White                                  90                91                                     90               91                           87                    93                                     85               96                       95               85               
  Black                                  7                 6                                      9                6                            8                     6                                      12               2                        3                12               
  Other                                  3                 3                                      2                3                            5                     1                                      3                2                        2                3                
  *Contributing cause*                                                                                                                                                                                                                                                                   
  *of AKI, %*                                                               0.35                                                      0.46                                             0.34                                                    0.89                                      0.66
  Ischemic                               29                20                                     25               30                           26                    30                                     26               30                       26               32               
  Nephro toxic                           15                23                                     20               13                           15                    16                                     17               15                       17               15               
  Septic                                 9                 11                                     11               8                            6                     12                                     10               9                        8                10               
  Multifactorial/other                   33                40                                     32               36                           40                    29                                     33               34                       37               30               
  *Coexisting conditions,*               *%*                                                                                                                                                                                                                                             
  DM                                     45                43               0.86                  46               43                 0.68      44                    45               0.93                  40               48               0.18    48               42               0.34
  Heart failure                          17                9                0.20                  16               16                 0.95      14                    17               0.46                  20               13               0.16    15               18               0.62
  Cirrhosis                              7                 11               0.31                  9                5                  0.26      9                     7                0.53                  7                8                0.65    8                4                0.12
  CLD                                    19                14               0.51                  15               21                 0.25      21                    17               0.44                  21               16               0.29    19               18               0.81
  CKD                                    68                69               0.94                  69               68                 0.87      70                    65               0.52                  71               66               0.43    69               65               0.48
  *APACHE II score*                      20 (7)            18 (5)           0.176                 20 (6)           20 (7)             0.84      19 (6)                20 (7)           0.21                  20 (7)           19 (6)           0.23    19 (6)           21 (7)           0.01
  *Sepsis, %*                            45                26               0.03                  44               42                 0.81      37                    47               0.09                  42               45               0.62    43               43               0.95
  *Shock, %*                             30                11               0.02                  24               31                 0.20      24                    30               0.29                  22               34               0.04    30               25               0.35
  *Serum creatinine, mg/dl*                                                                                                                                                                                                                                                              
  Baseline value                         1.6 (0.8)         1.4 (0.5)        0.37                  1.6 (0.8)        1.5 (0.6)          0.82      1.6 (0.6)             1.5 (0.8)        0.56                  1.6 (0.8)        1.5 (0.6)        0.07    1.5 (0.6)        1.6 (0.8)        0.53
  Enrollment value                       3.6 (1.8)         3.5 (1.4)        0.96                  3.7 (1.9)        3.5 (1.6)          0.46      3.6 (1.7)             3.5 (1.8)        0.55                  3.7 (1.8)        3.4 (1.7)        0.20    3.4 (1.6)        3.6 (1.9)        0.36
  Peak                                   4.4 (2.7)         4.1 (1.8)        0.61                  4.7 (3.2)        4.1 (1.9)          0.08      4.3 (2.1)             4.4 (2.9)        0.65                  4.5 (3.0)        4.2 (2.2)        0.34    4.4 (3.0)        4.3 (2.0)        0.72
  Discharge                              2.5 (1.7)         2.3 (1.6)        0.37                  2.5 (1.8)        2.5 (1.7)          0.89      2.5 (1.6)             2.5 (1.8)        0.85                  2.7 (1.9)        2.4 (1.5)        0.12    2.4 (1.7)        2.7 (1.7)        0.18
  *Urine output, Vday*                   1.2 (1.1)         1.5 (1.2)        0.25                  1.2 (1.0)        1.3 (1.2)          0.69      1.3 (1.2)             1.2 (1.0)        0.33                  1.4 (1.1)        1.2 (1.0)        0.12    1.2 (1.0)        1.4 (1.1)        0.39
  *AKI stage at enrollment, %*                                              0.47                                                      0.11                                             0.41                                                    0.68                                      0.87
  Stage 1                                43                43                                     36               49                           43                    43                                     41               46                       44               42               
  Stage 2                                4                 9                                      5                4                            7                     3                                      45               5                        5                4                
  Stage 3                                53                49                                     59               47                           50                    54                                     55               49                       51               54               
  *Oxidative stress markers*                                                                                                                                                                                                                                                             
  Plasma nitro-tyrosine, nM              12 (9, 23)        11 (10, 24)      0.29                  12 (9, 24)       12 (9, 22)         0.45      12 (9,21)             12 (9, 24)       0.38                  12 (9, 22)       12 (8, 23)       0.30    12 (9, 23)       12 (9, 22)       0.21
  Urinary 15-F~2t~-iso prostane, ng/mg   1.1 (0.6, 2.2)    1.1 (0.6, 4.0)   0.42                  1.1 (0.6, 2.8)   1.1 (0.6, 2.0)     0.49      1.2 (0.6, 2.6)        1.0 (0.6, 2.0)   0.56                  1.0 (0.5, 2.0)   1.2 (0.6, 2.4)   0.87    1.2 (0.7, 2.7)   0.9 (0.5, 1.7)   0.73

CKD = Chronic kidney disease; CLD = chronic lung disease; DM = diabetes mellitus. Continuous variables are presented as means (SD) or medians (25th, 75th percentile), and categorical variables as percentages. Missing genotyping data: rs3794624 (n = 5), rs4782390 (n = 2), and rs1049255 (n = 6).

###### 

Association of the 5 *CYBA* gene polymorphisms with adverse outcomes in the AKI cohort

  Predicted variable                                     Dialysis requirement or in-hospital death   Dialysis requirement, mechanical ventilation, or in-hospital death                              
  ------------------------------------------------------ ------------------------------------------- -------------------------------------------------------------------- ------ ------ ------------ ------
  *rs8854 (A-allele vs. G/G)*                                                                                                                                                                        
  Unadjusted                                             0.40                                        0.19,0.88                                                            0.02   0.43   0.20, 0.90   0.03
  Model 1                                                0.39                                        0.18,0.85                                                            0.02   0.42   0.20, 0.89   0.02
  Model 2                                                0.41                                        0.18,0.96                                                            0.04   0.43   0.18,0.99    0.05
                                                                                                                                                                                                     
  *rs3794624 (A-allele vs. G/G)*                                                                                                                                                                     
  Unadjusted                                             0.92                                        0.56,1.50                                                            0.73   1.07   0.65,1.75    0.79
  Model 1                                                0.91                                        0.55,1.49                                                            0.71   1.06   0.65,1.73    0.82
  Model 2                                                0.93                                        0.54,1.62                                                            0.80   1.17   0.66,2.07    0.59
                                                                                                                                                                                                     
  *rs4673 (T-alkie vs. GIG)*                                                                                                                                                                         
  Unadjusted                                             1.69                                        1.03,2.79                                                            0.04   1.37   0.83,2.24    0.21
  Model 1                                                1.66                                        1.00,2.74                                                            0.05   1.35   0.82,2.23    0.24
  Model 2                                                1.53                                        0.88,2.68                                                            0.13   1.19   0.67,2.11    0.55
                                                                                                                                                                                                     
  *rs4782390 (T-allele vs. A/A)*                                                                                                                                                                     
  Unadjusted                                             0.84                                        0.52,1.37                                                            0.45   1.12   0.69,1.82    0.65
  Model 1                                                0.82                                        0.49,1.35                                                            0.43   1.07   0.65,1.77    0.78
  Model 2                                                0.92                                        0.53,1.60                                                            0.77   1.37   0.77, 2.45   0.29
                                                                                                                                                                                                     
  *rsl049255 (G-allele vs. A/A)*                                                                                                                                                                     
  Unadjusted                                             1.66                                        1.01,2.73                                                            0.05   1.44   0.88,2.37    0.15
  Model 1                                                1.74                                        1.04,2.89                                                            0.03   1.51   0.91,2.51    0.11
  Model 2                                                1.36                                        0.77,2.41                                                            0.29   1.08   0.60,1.96    0.79
                                                                                                                                                                                                     
  *A-A-G-G haplotype*[^a^](#T3F1){ref-type="table-fn"}                                                                                                                                               
  Unadjusted                                                                                                                                                              0.07                       0.09
   1 copy (vs. none)                                     1.81                                        1.07,3.08                                                            0.03   1.58   0.93,2.69    0.09
   2 copies (vs. none)                                   1.06                                        0.50,2.23                                                            0.88   0.77   0.37,1.61    0.48
  Model 1                                                                                                                                                                 0.09                       0.12
   1 copy (vs. none)                                     1.76                                        1.03,3.01                                                            0.04   1.55   0.91,2.66    0.11
   2 copies (vs. none)                                   1.06                                        0.50,2.24                                                            0.88   0.78   0.37,1.64    0.50
  Model 2                                                                                                                                                                 0.09                       0.05
   1 copy (vs. none)                                     1.80                                        0.99, 3.29                                                           0.05   1.61   0.86,3.01    0.13
   2 copies (vs. none)                                   0.87                                        0.38,2.00                                                            0.75   0.54   0.23,1.28    0.16

Model 1 is adjusted for sex, race, and age; model 2 is adjusted for sex, race, and APACHE II score.

The haplotype was generated from the *CYBA* rs4782390, rs4673, rs3794624, and rs8854 polymorphisms that were in Hardy-Weinberg equilibrium.
